Statin-Mediated Low-Density Lipoprotein Lowering in Chronic Congestive Heart Failure
Autor: | Timothy J. Vittorio, Hassan Alkhawam, Kathleen M. Grady, Gabriel Wagman, Mohammed El-Hunjul, Mark R. Kahn, Constantine E. Kosmas |
---|---|
Rok vydání: | 2014 |
Předmět: |
Male
medicine.medical_specialty Statin Ubiquinone medicine.drug_class chemistry.chemical_compound Internal medicine Humans Medicine cardiovascular diseases Adverse effect Aged Randomized Controlled Trials as Topic Aged 80 and over Heart Failure Coenzyme Q10 business.industry Cholesterol General Medicine medicine.disease Endotoxins Lipoproteins LDL Survival Rate Clinical trial Treatment Outcome chemistry Low-density lipoprotein Heart failure Chronic Disease Cardiology Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors business Lipoprotein |
Zdroj: | The American Journal of the Medical Sciences. 347:14-22 |
ISSN: | 0002-9629 |
DOI: | 10.1097/maj.0b013e318273514c |
Popis: | Many theories and clinical trials have attempted to address the effect of low-density lipoprotein (LDL) lowering in chronic congestive heart failure (CHF). The current evidence suggests that there is no convincing reason for administering statins to patients with nonischemic heart failure. Although they do not reduce the mortality rate, statins reduce LDL cholesterol and may provide some benefit to patients with ischemic heart failure. in contrast, some authors believe that statin therapy may actually worsen outcomes in patients with CHF, especially if there is excessive reduction in LDL cholesterol. This review discusses the theories attempting to link the adverse effects of statin-mediated LDL lowering in CHF to increased levels of endotoxin or reduced levels of coenzyme Q10. In addition, the 2 largest randomized, double-blind, placebo-controlled clinical trials (CoRoNA and Gissi-HF) were discussed. it is clear that more trials are needed to definitely ascertain the effect of statins on CHF. |
Databáze: | OpenAIRE |
Externí odkaz: |